EVALUATION OF ADVERSE DRUG REACTIONS AND DRUGDRUG INTERACTIONS IN TUBERCULOSIS PATIENTS RECEIVING DOTS THERAPY IN A TERTIARY CARE HOSPITAL

Read full text Summarise with VIRAT
Authors: Harsha T, Sreejith K, Apsara A M, Sherin Shahana K, Jasira J
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs. The World Health Organization–recommended DOTS strategy employs first-line drugs—isoniazid, rifampicin, pyrazinamide, and ethambutol—to improve adherence and prevent resistance. However, prolonged multidrug therapy increases the risk of adverse drug reactions (ADRs) and drug–drug interactions (DDIs). This cross-sectional study, conducted over six months in a tertiary care hospital, included 250 TB patients receiving DOTS therapy. Data on demographics, treatment details, ADRs, and DDIs were systematically collected. A total of 230 patients (92%) experienced at least one ADR, with the highest incidence in the 50–59-year age group and a male predominance. Hepatotoxicity was the most common ADR. Most reactions were mild to moderate and assessed as probable. A significant number of DDIs were also observed, mainly due to polypharmacy. In conclusion, ADRs and DDIs are common during DOTS therapy. Although most are manageable, regular monitoring is essential to ensure patient safety and optimize treatment outcomes.

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Pharmacovigilance and Adverse Drug Reactions Drug-Induced Hepatotoxicity and Protection

Publication details

Journal / source
JOURNAL OF EMERGING TRENDS AND NOVEL RESEARCH
Volume
4
Issue
3
Publication date
1 January 2026
Language
EN